ObsEva SA (OBSV) Gets a Buy Rating from H.C. Wainwright


In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ObsEva SA (OBSV), with a price target of $44. The company’s shares closed yesterday at $12.38.

Selvaraju commented:

“We remind investors that IMPLANT 4 was initiated in lte November 2018, and view it as a further demonstration of ObsEva’s strength in execution that the study was fully enrolled on time. In anticipation of further progress in 2019 with linzagolix, nolasiban and OBE022, we reiterate our Buy rating and 12- month target of $44 per share.”

According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.4% and a 25.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on ObsEva SA is a Strong Buy with an average price target of $33.60, a 171.4% upside from current levels. In a report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $38 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.35 and a one-year low of $10.23. Currently, ObsEva SA has an average volume of 46.69K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ObsEva SA engages in the development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts